HK1034912A1 - Novel fatty analogues for the treatment of obesity - Google Patents

Novel fatty analogues for the treatment of obesity

Info

Publication number
HK1034912A1
HK1034912A1 HK01105690A HK01105690A HK1034912A1 HK 1034912 A1 HK1034912 A1 HK 1034912A1 HK 01105690 A HK01105690 A HK 01105690A HK 01105690 A HK01105690 A HK 01105690A HK 1034912 A1 HK1034912 A1 HK 1034912A1
Authority
HK
Hong Kong
Prior art keywords
sub
treatment
obesity
novel fatty
analogues
Prior art date
Application number
HK01105690A
Other languages
English (en)
Inventor
Rolf Berge
Original Assignee
Thia Medica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica filed Critical Thia Medica
Publication of HK1034912A1 publication Critical patent/HK1034912A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
HK01105690A 1998-05-08 2001-08-14 Novel fatty analogues for the treatment of obesity HK1034912A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
PCT/NO1999/000135 WO1999058121A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver

Publications (1)

Publication Number Publication Date
HK1034912A1 true HK1034912A1 (en) 2001-11-09

Family

ID=19907879

Family Applications (3)

Application Number Title Priority Date Filing Date
HK01105684A HK1034909A1 (en) 1998-05-08 2001-08-14 Novel fatty analogues for the treatment of diabetes
HK01105690A HK1034912A1 (en) 1998-05-08 2001-08-14 Novel fatty analogues for the treatment of obesity
HK01105689A HK1034911A1 (en) 1998-05-08 2001-08-14 Novel fatty acid analogues for the treatment of secondary restenosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK01105684A HK1034909A1 (en) 1998-05-08 2001-08-14 Novel fatty analogues for the treatment of diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK01105689A HK1034911A1 (en) 1998-05-08 2001-08-14 Novel fatty acid analogues for the treatment of secondary restenosis

Country Status (18)

Country Link
US (4) US6365628B1 (de)
EP (5) EP1284139B1 (de)
JP (3) JP5057003B2 (de)
KR (3) KR100701502B1 (de)
CN (3) CN1245157C (de)
AT (5) ATE245416T1 (de)
AU (4) AU7240398A (de)
BR (2) BR9910296A (de)
CA (3) CA2331408C (de)
DE (5) DE69932864D1 (de)
DK (3) DK1075258T3 (de)
ES (3) ES2204142T3 (de)
HK (3) HK1034909A1 (de)
NO (3) NO20005461L (de)
NZ (3) NZ508045A (de)
PT (2) PT1075259E (de)
RU (3) RU2221558C2 (de)
WO (4) WO1999058120A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
CA2388754C (en) * 1999-10-13 2010-07-13 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
AU2003241823A1 (en) * 2002-05-28 2003-12-12 Ajinomoto Co., Inc. Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
EP1515978A1 (de) * 2002-06-20 2005-03-23 IC Vec Limited Schwefelhaltige phospholipidderivate
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
CA2497827A1 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
BR0314799A (pt) * 2002-09-27 2005-07-26 Market Biosciences Corp Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
KR20050071565A (ko) * 2002-10-10 2005-07-07 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 지방 알콜의 염기성 에스테르 및 이들의 항염증제 또는면역조절제로서의 용도
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
JP2006519229A (ja) * 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
US20090215895A1 (en) * 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
JP2008501110A (ja) * 2004-05-28 2008-01-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 覚醒ラットにおける新しい静脈内薬物投与および血液サンプリングモデル
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
EP2275140B1 (de) * 2004-07-19 2017-11-01 Bergen Teknologioverforing AS Zusammensetzung enthaltend Pflanzen- oder Fischöl und nicht-oxidierbaren Fettsäuren-enthaltenden Komponenten
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006083439A2 (en) * 2004-12-28 2006-08-10 The Research Foundation Of State University Of New York At Buffalo Method for lowering serum homocysteine
WO2006088798A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
US20090203778A1 (en) * 2005-05-04 2009-08-13 Morten Bryhn Fatty acid analogues, i.e. including dha derivatives for uses as a medicament
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
CA2666846C (en) 2006-10-20 2018-04-10 Cpd, Llc Method of restoring the incretin effect
CN101535238A (zh) * 2006-11-01 2009-09-16 普罗诺瓦生物医药挪威公司 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
WO2008132552A2 (en) * 2006-11-01 2008-11-06 Pronova Biopharma Norge As Omega-3 lipid compounds
EP2117301A4 (de) * 2007-02-26 2010-04-14 Yeda Res & Dev Verwendung langkettiger alkoholderivate zur behandlung von kreisrundem haarausfall
EP2114155A4 (de) * 2007-02-26 2014-04-16 Yeda Res & Dev Enantiomere aus amino-phenyl-essigsäure-octadez-9-(z)-enylester, ihre salze und anwendungen davon
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
EP2217558A1 (de) * 2007-10-31 2010-08-18 Pronova Biopharma Norge AS Neue dha-derivate und ihre verwendung als medikamente
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
JP5373888B2 (ja) * 2008-04-29 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｐｔ２インヒビターとしての４−トリメチルアンモニオ−ブチラート類
EP2147910A1 (de) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
TWI558395B (zh) 2009-05-08 2016-11-21 普諾華生物製藥諾治股份有限公司 新穎的脂質化合物
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
EP2459251B1 (de) 2009-07-30 2014-03-12 Tandem Diabetes Care, Inc. Infusionspumpensystem mit einwegkartusche mit druckentlüftung und druckfeedback
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
BR112013003658B1 (pt) 2010-07-28 2022-02-22 Life Technologies Corporation Composição farmacêutica compreendendo ácido graxo, carboidrato e lipídio de isoprenoide modificados com azida, uso de tais componentes e método para inibir infectividade de um vírus
EA028535B1 (ru) 2010-11-05 2017-11-30 Пронова Биофарма Норге Ас Способы лечения с применением липидных соединений
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3578170A1 (de) 2013-02-28 2019-12-11 Basf As Zusammensetzung mit einer lipidverbindung, einem triglycerid und einem tensid sowie verfahren zur verwendung davon
CA2904898C (en) 2013-03-11 2019-10-15 Jan Remmereit Lipid compositions containing bioactive fatty acids
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
WO2016073615A1 (en) 2014-11-07 2016-05-12 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
KR102644400B1 (ko) 2015-04-28 2024-03-06 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
WO2019083816A1 (en) * 2017-10-23 2019-05-02 Epitracker, Inc. FATTY ACID ANALOGUES AND THEIR USE IN THE TREATMENT OF STATES RELATED TO METABOLIC SYNDROME
CA3084728A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
WO2020180814A1 (en) * 2019-03-04 2020-09-10 Epitracker, Inc. Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
DE69622722T2 (de) * 1996-11-20 2003-02-27 Nutricia Nv Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions

Also Published As

Publication number Publication date
DK1075258T3 (da) 2003-12-01
NO333143B1 (no) 2013-03-18
BR9910297A (pt) 2002-01-02
ES2207253T3 (es) 2004-05-16
ATE245416T1 (de) 2003-08-15
CA2331395A1 (en) 1999-11-18
RU2223095C2 (ru) 2004-02-10
AU762792B2 (en) 2003-07-03
AU5451799A (en) 1999-11-29
PT1075259E (pt) 2003-12-31
DE69910559D1 (de) 2003-09-25
ES2204142T3 (es) 2004-04-16
NO20005461L (no) 2001-01-08
EP1075260A2 (de) 2001-02-14
RU2221558C2 (ru) 2004-01-20
AU7240398A (en) 1999-11-29
EP1075258A1 (de) 2001-02-14
DK1075260T3 (da) 2006-02-06
US6441036B1 (en) 2002-08-27
AU762790B2 (en) 2003-07-03
WO1999058120A1 (en) 1999-11-18
DE69932864D1 (de) 2006-09-28
DE69910559T2 (de) 2004-06-17
HK1034911A1 (en) 2001-11-09
KR20010043315A (ko) 2001-05-25
NO20005463D0 (no) 2000-10-30
US7026356B2 (en) 2006-04-11
ATE336239T1 (de) 2006-09-15
CA2331395C (en) 2008-10-14
DE69909775D1 (de) 2003-08-28
WO1999058122A1 (en) 1999-11-18
ES2251218T3 (es) 2006-04-16
EP1075259B1 (de) 2003-07-23
US6417232B1 (en) 2002-07-09
ATE334666T1 (de) 2006-08-15
JP2002514596A (ja) 2002-05-21
KR100701502B1 (ko) 2007-04-02
KR20010043314A (ko) 2001-05-25
NO20005462D0 (no) 2000-10-30
EP1075260B1 (de) 2005-10-19
CN1245157C (zh) 2006-03-15
BR9910296A (pt) 2002-01-15
DK1075259T3 (da) 2003-11-03
PT1075258E (pt) 2004-01-30
NO20005462L (no) 2001-01-08
WO1999058121A1 (en) 1999-11-18
JP2002514595A (ja) 2002-05-21
US20020198259A1 (en) 2002-12-26
CA2331393C (en) 2009-08-11
EP1285652A1 (de) 2003-02-26
CA2331393A1 (en) 1999-11-18
DE69927805T2 (de) 2006-07-06
AU4936699A (en) 1999-11-29
ATE306916T1 (de) 2005-11-15
WO1999058123A3 (en) 2000-03-09
KR100822077B1 (ko) 2008-04-14
NZ508045A (en) 2003-08-29
NO20005461D0 (no) 2000-10-30
CA2331408A1 (en) 1999-11-18
CN1300211A (zh) 2001-06-20
DE69909775T2 (de) 2004-06-03
CN1244323C (zh) 2006-03-08
NZ508046A (en) 2003-08-29
JP4465672B2 (ja) 2010-05-19
WO1999058123A2 (en) 1999-11-18
HK1034909A1 (en) 2001-11-09
EP1075259A1 (de) 2001-02-14
RU2219920C2 (ru) 2003-12-27
ATE247464T1 (de) 2003-09-15
KR100701503B1 (ko) 2007-04-02
NZ508047A (en) 2003-05-30
DE69927805D1 (de) 2006-03-02
CA2331408C (en) 2008-10-21
AU761355B2 (en) 2003-06-05
EP1075258B1 (de) 2003-08-20
EP1285652B1 (de) 2006-08-16
EP1284139A1 (de) 2003-02-19
JP5057003B2 (ja) 2012-10-24
US6365628B1 (en) 2002-04-02
EP1284139B1 (de) 2006-08-02
JP2002514594A (ja) 2002-05-21
CN1223343C (zh) 2005-10-19
CN1300212A (zh) 2001-06-20
NO20005463L (no) 2001-01-08
DE69932645D1 (de) 2006-09-14
CN1302204A (zh) 2001-07-04
AU4936799A (en) 1999-11-29
KR20010043316A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
HK1034912A1 (en) Novel fatty analogues for the treatment of obesity
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
BG103485A (en) Ketobanzamides as calpain inhibitors
TW283716B (de)
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
NZ279397A (en) Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives and pharmaceutucal compositions
RS19504A (en) Novel compounds and compositions as cathepsin inhibitors
HK1068332A1 (en) Pyrane derivatives as both ace-and nep-inhibitors
PL352551A1 (en) C16 unsaturated analoques of prostaglandines selective in respect to fp
WO2002008161A3 (en) Polymerization inhibitor for vinyl-containing materials
PL354959A1 (en) Silicon compounds derived from ascorbic acid
GB9806409D0 (en) Processes for preparing intermediates
GB9920959D0 (en) Novel process
GR3029590T3 (en) Crystalline, polymorphic form of (s,s,s)-n-(1- 2-carboxy-3-(n?2 -mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosine
PL363923A1 (en) Chloromethylation of thiophene
YU70799A (sh) Derivati tiazofurina
WO2003004652A3 (en) Use of a tyrosine recombinase for genetic engineering

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110423